Stabilis - Monographie - Insulin

StabilisInsulin

Tradename

Actrapid Texte introuvable (616, ), Austria, Belgium, Croatia, Denmark,Finland, France, Great Britain, Greece, Hungary, Ireland, Italy,Netherlands, Norway, Poland, Portugal, Republic of South Africa,Russian, Serbia, Slovenia, Spain, Sweden, Switzerland, Turkey

Biosulin RussianGensulin PolandHumaject Croatia, Poland, SloveniaHumaplus SpainHumasulin Austria, SwitzerlandHumasulina SpainHumulin R Texte introuvable (616, ), Canada, Croatia, Denmark, Great

Britain, Greece, Poland, Republic of South Africa, Slovenia,Turkey, United States of America

Humuline Belgium, NetherlandsInsuman Texte introuvable (616, ), Austria, Denmark, Finland, France,

Great Britain, Ireland, Netherlands, Norway, Russian, Sweden,Switzerland

Isuhuman PortugalNovolin CanadaUmuline FranceVelosulin Texte introuvable (616, ), Austria, Belgium, FranceVelosuline United States of America

Stability in solutions

0,1 UI/ml 2-8°C 8 2091

0,1 UI/ml 25°C 24 2091

0,1 UI/ml 37°C 24 2091

0,004 UI/ml 25°C 24 2164

0,01 UI/ml 25°C 24 2164

0,02 UI/ml 25°C 24 2164

0,04 UI/ml 25°C 24 2164

0,01 UI/ml 25°C 6 2164

www.stabilis.org - 27/11/2021 11:21 - Page 1

0,02 UI/ml 25°C 6 2164

0,04 UI/ml 25°C 6 2164

100 UI/ml 37°C 48 803

0,01 UI/ml 25°C 6 2164

0,02 UI/ml 25°C 6 2164

0,04 UI/ml 25°C 6 2164

100 UI/ml 3-5°C 28 468

1 UI/ml 2-6°C 180 3224

1 UI/ml 23-27°C 30 3224

100 UI/ml 3-5°C 28 468

500 UI/ml 4°C 28 4309

Stability of mixtures

0,8 UI/ml 22°C-23°C Milrinone lactate : 0,2 mg/ml 4 813

1 UI/ml 25°C Ranitidine hydrochloride : 1 mg/ml 1 208

Factors which affect stability

857

1091

208464

11751242209133101242

1245


Compatibility

Insulin : 1 UI/mlAlprostadil : 20 µg/ml 4491

Insulin : 2 UI/mlAmiodarone hydrochloride : 15 mg/ml 3823

Insulin : 1 UI/mlAmiodarone hydrochloride : 25 mg/ml 4119

Insulin : 1 UI/mlAmiodarone hydrochloride : 12,5 mg/ml 4119

Insulin : 1 UI/mlAmiodarone hydrochloride : 0,6 >> 9,75 mg/ml 4119

InsulinAmiodarone hydrochloride 3464

Insulin : 1 UI/mlAmiodarone hydrochloride : 4.8 mg/ml 295

Insulin : 1 UI/mlAmoxicillin sodium : 20.83 & 83.3 mg/ml 4254

Insulin : 0.2 UI/mlAmpicillin sodium : 20 mg/ml 129

Insulin : 0.2 UI/mlAmpicillin sodium - sulbactam sodium : 30 mg/ml 129

Insulin : 0.2 UI/mlAztreonam : 20 mg/ml 129

Insulin : 1 UI/mlBretylium tosilate : 1 mg/ml 1193

Insulin : 100 UI/mlCaffeine : 10 mg/ml 3964

Insulin : 1 UI/mlCaspofungin acetate : 0,7 mg/ml 2247

Insulin : 1 UI/mlCaspofungin acetate : 0.5 mg/ml 2233

Insulin : 0.2 UI/mlCefazolin sodium : 20 mg/ml 129

Insulin : 100 UI/mlCefepime dihydrochloride : 125 mg/ml 2141

Insulin : 1 UI/mlCefiderocol sulfate tosylate : 20 mg/mL 4528

Insulin : 1 UI/mlCefotaxime sodium : 83.3 mg/ml 4254

Insulin : 1 UI/mlCeftaroline fosamil : 2,22 mg/ml 3249

Insulin : 1 UI/mlCeftaroline fosamil : 2,22 mg/ml 3249

Insulin : 100 UI/mlCeftazidime : 125 mg/ml 2141

Insulin : 1 UI/mlCeftobiprole : 2 mg/ml 2269

Insulin : 1 UI/mlCeftobiprole : 2 mg/ml 2269


Insulin : 1 UI/mlCeftolozane / tazobactam : 10/5 mg/ml 3828

Insulin : 0.1 UI/mlCimetidine hydrochloride : 1.2 & 5 mg/ml 1201

Insulin : 2 UI/mlCisatracurium besylate : 5 mg/ml 3823

Insulin : 1 UI/mlCisatracurium besylate : 1 mg/ml 3429

Insulin : 1 UI/mlClonidine hydrochloride : 0.0075 mg/ml 1506

Insulin : 100 UI/mlCloxacillin sodium : 100 mg/ml 3012

Insulin : 1 UI/mlCo-trimoxazole : 3.2/0.64 & 80/16 mg/ml 4254

InsulinCytarabine 3580

Insulin : 2 UI/mlDiclofenac : 3 mg/ml 3823

Insulin : 0.4 UI/mlDiltiazem hydrochloride : 5 mg/ml 198

Insulin : 100 UI/mlDiltiazem hydrochloride : 1 & 5 mg/ml 198

Insulin : 1 UI/mlDobutamine hydrochloride : 1 mg/ml 1058



Insulin : 1 UI/mlDopamine hydrochloride : 8 mg/ml 1506

Insulin : 1 UI/mlDopamine hydrochloride : 3.2 mg/ml 295

Insulin : 100 UI/mlDopamine hydrochloride : 3,2 mg/ml 4389

Insulin : 1 UI/mlDoripenem : 5 mg/ml 2262

Insulin : 1 UI/mlDoxapram hydrochloride : 2 mg/ml 1802

Insulin : 1 UI/mlEravacycline : 0,6 mg/ml 4434

Insulin : 1 UI/mlEsmolol hydrochloride : 40 mg/ml 295

Insulin : 1 UI/mlEsomeprazole sodium : 0.32 mg/ml 1506

Insulin : 0.03 UI/mlFamotidine : 0.2 mg/ml 398

Insulin : 1 UI/mlFosfomycin : 30 mg/ml 4055

Insulin : 2 UI/mlFurosemide : 10 mg/ml 3134




InsulinFurosemide 3465

Insulin : 0.2 UI/mlGentamicin sulfate : 1.2 >> 2 mg/ml 129

Insulin : 1 UI/mlGlycerophosphate disodium 4332

Insulin : 2 UI/mlHaloperidol lactate : 0.5 mg/ml 3823

Insulin : 0.2 UI/mlHeparin sodium : 60 UI/ml 129

Insulin : 2 UI/mlHeparin sodium : 500 UI/ml 3823

Insulin : 1 UI/mlIbuprofen lysinate : 10 mg/ml 4419

Insulin : 0.1 UI/mlIbuprofen lysinate : 10 mg/ml 4419

Insulin : 1 UI/mlImipenem-Cilastatin / Relebactam : 5 mg/ml 4433

Insulin : 1 UI/mlIndomethacin sodium trihydrate : 1 mg/ml 467

Insulin : 1 UI/mlIsavuconazonium sulfate : 1.5 mg/ml 3829

Insulin : 100 UI/mlKetamine hydrochloride : 50 mg/ml 2109

Insulin : 1 UI/mlLabetalol hydrochloride : 5 mg/ml 295

Insulin : 100 UI/mlLevofloxacine : 5 mg/ml 1072

Insulin : 1 UI/mlLevofloxacine : 5 mg/ml 1072

Insulin : 1 UI/mlLidocaine hydrochloride : 2 mg/ml 619

Insulin : 1 UI/mlLidocaine hydrochloride : 2 mg/ml 619

Insulin : 1 UI/mlLinezolid : 2 mg/ml 4254

Insulin : 0.2 UI/mlMagnesium sulfate : 40 mg/ml 129

Insulin : 100 UI/mlMeropenem : 50 mg/ml 4319

Insulin : 0.2 UI/mlMeropenem : 1 & 50 mg/ml 266

Insulin : 1 UI/mlMeropenem : 1 & 20 mg/ml 266

Insulin : 1 UI/mlMethadone hydrochloride : 0.2 mg/ml 1506

Insulin : 1 UI/mlMicafungin : 1.5 mg/ml 2108

Insulin : 2 UI/mlMidazolam hydrochloride : 2.1 mg/ml 3823


Insulin : 1 UI/mlMidazolam hydrochloride : 4 mg/ml 1506

Insulin : 1 UI/mlMidazolam hydrochloride : 1 mg/ml 295

Insulin : 2 UI/mlMilrinone lactate : 0.8 mg/ml 813

Insulin : 0.2 UI/mlMorphine sulfate : 1 mg/ml 406

Insulin : 1 UI/mlMorphine sulfate : 1 mg/ml 295

Insulin : 0.2 UI/mlMorphine sulfate : 5 mg/ml 129

Insulin : 100 UI/mlN-acetylcysteine : 200 mg/ml 3766

Insulin : 0.2 UI/mlNafcillin sodium : 20 & 40 mg/ml 129

Insulin : 100 UI/mlNaloxone hydrochloride : 0.4 mg/ml 3408

Insulin : 2 UI/mlNitroglycerin : 0.2 mg/ml 3823

Insulin : 1 UI/mlNitroglycerin : 0.2 mg/ml 295

Insulin : 1 UI/mlNitroprusside sodium : 0.2 mg/ml 295

Insulin : 1 UI/mlNorepinephrine bitartrate : 0.32 mg/ml 1506

Insulin : 1 UI/mlNorepinephrine bitartrate : 0.064 mg/ml 295

Insulin : 1 UI/mlOritavancin : 0.8 >>2 mg/ml 3152

Insulin : 1 UI/mlOrnidazole : 31.25 mg/ml 4254

Insulin : 0.2 UI/mlOxytocin : 0.02 UI/ml 129

InsulinPantoprazole sodium 2090

Insulin : 5 >> 50 UI/mlPantoprazole sodium : 0.16 >> 0.8 mg/ml 1902

Insulin : 0,2 UI/mlPentoxifyllin : 5 mg/ml 4543

Insulin : 0.2 UI/mlPethidine hydrochloride : 10 mg/ml 406

Insulin : 0.2 UI/mlPethidine hydrochloride : 50 mg/ml 129

Insulin : 1 UI/mlPiperacillin sodium / tazobactam : 166/20.83 mg/ml 4254

Insulin : 1 UI/mlPlazomicin sulfate : 24 mg/ml 4145

Insulin : 40 UI/mlPotassium chloride : 40 mEq/l 730

Insulin : 40 UI/mlPotassium chloride : 40 mEq/l 730


InsulinPotassium phosphate 3781

Insulin : 1 UI/mlPropofol : 10 mg/ml 300

Insulin : 1 UI/mlRemifentanil hydrochloride : 120 µg/ml 3176

InsulinRocuronium bromide 3564

Insulin : 100 UI/mlSalbutamol sulfate : 1 mg/ml 3216

Insulin : 2 UI/mlSodium bicarbonate : 84 mg/ml 3212

InsulinSodium bicarbonate 3466

Insulin : 2 UI/mlSodium bicarbonate : 84 mg/ml 3823

Insulin : 100 UI/mlSugammadex : 100 mg/ml 3372

Insulin : 0,1 UI/mlTacrolimus : 1000 µg/ml 479

Insulin : 1 UI/mlTedizolid phosphate : 0.8 mg/ml 3827

Insulin : 100 UI/mlTemocilline : 83.33 mg/ml 2231

Insulin : 0.2 UI/mlTerbutaline sulfate : 0.02 mg/ml 129

InsulinThiopental sodium : 25 mg/ml 3767

Insulin : 0.2 UI/mlTicarcillin / clavulanic acid : 31 mg/ml 129

Insulin : 2 UI/ml 939Insulin : 2 UI/mlTirofiban : 250 µg/ml 3823

Insulin : 0.2 UI/mlTobramycin sulfate : 1.6 & 2 mg/ml 129

Insulin : 2 UI/mlUrapidil : 5 mg/ml 3823

Insulin : 0.2 UI/mlVancomycin hydrochloride : 4 mg/ml 129

Insulin 4567Insulin : 1 UI/ml 1415Insulin : 100 UI/ml 4603Insulin : 100 UI/mlVancomycin hydrochloride : 10 mg/ml 3385

Insulin : 1 UI/mlVasopressin : 0.2 UI/ml 2017

Insulin : 0,2 UI/mlVerapamil hydrochloride : 0,08 mg/ml 706

Insulin : 1 UI/ml 301


Route of administration

References

Type Publication129 Journal Smythe M, Malouf E.

Visual compatibility of insulin with secondary intravenous drugs in admixtures.Am J Hosp Pharm 1991 ; 48: 125-126.

198 Journal Gayed AA, Kheshary PR, Hinkle RL.Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.Am J Health-Syst Pharm 1995 ; 52: 516-520.

208 Journal Nolan PE, Hoyer GL, Ledoux JH, Fox JL.Stability of ranitidine hydrochloride and human insulin in 0.9% sodium chloride injection.Am J Health-Syst Pharm 1997 ; 54: 1304-1306.

266 Journal Patel PR.Compatibility of meropenem with commonly used injectable drugs.Am J Health-Syst Pharm 1996 ; 53: 2853-2855.

295 Journal Yamashita SK, Walker SE, Choudhury T, Iazzetta J.Compatibility of selected critical care drugs during Y-site administration.Am J Health-Syst Pharm 1996 ; 53: 1048-1051.

300 Journal Trissel LA, Gilbert DL, Martinez JF.Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1287-1292.

301 Journal Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1295-1300.

398 Journal Jay GT, Fanikos J, Souney PF.Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.Am J Hosp Pharm 1988 ; 45: 1556-1557.

406 Journal Smythe MA, Patel MA, Gasloli RA.Visual compatibility of narcotic analgesics with selected intravenous admixtures.Am J Hosp Pharm 1990 ; 47: 819-820.

464 Journal Furberg H, Kruse Jensen A, Salbu B.Effect of pretreatment with 0.9% sodium chloride or insulin solutions on the delivery of insuline from an infusionsystem.Am J Hosp Pharm 1986 ; 43: 2209-2213.

467 Journal Ishisaka DY, van Vleet J, Marquardt E.Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion.Am J Hosp Pharm 1991 ; 48: 2442-2443.

468 Journal Tarr BD, Campbell RK, Workman TM.Stability and sterility of biosynthetic human insulin stored in plastic insulin syringes for 28 days.Am J Hosp Pharm 1991 ; 48: 2631-2634.

479 Journal Min DI, Brown T, HWang GC.Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.Am J Hosp Pharm 1992 ; 49: 2964-2966.


619 Journal Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ.Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives.Am J Hosp Pharm 1982 ; 39: 1013-1015.

706 Journal Cutie MR.Compatibility of verapamil hydrochloride with other additives.Am J Hosp Pharm 1981 ; 38: 231.

730 Journal Allen LV, Saul Levinson R, Phisutsinthop D.Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.Am J Hosp Pharm 1977 ; 34: 939-943.

803 Journal Lougheed WD, Weymouth AB, Zinman B, Bernstein EA, Strack TR, Korbas AM, Janis LJ, Frank BH.Stability of insulin lispro in insulin infusion systems.Diabetes Care 1997 ; 20: 1061-1065.

813 Journal Akkermann SR, Zhang H, Mullins RE, Yaughn K.Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.Am J Health-Syst Pharm 1999 ; 56: 63-68.

857 Journal Kanke M, Eubanks JL, DeLuca PP.Binding of selected drugs to a “treated” inline filter.Am J Hosp Pharm 1983 ; 40: 1323-1328.

939 Journal Gilbar PJ, Groves CF.Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs duringsimulated Y-site injection.Aust J Hosp Pharm 1994 ; 24: 167-170.

1041 Journal Hasegawa GR, Eder JF.Visual compatibility of dobutamine hydrochloride with other injectable drugs.Am J Hosp Pharm 1984 ; 41: 949-951.

1058 Journal Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ.Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives.Am J Hosp Pharm 1983 ; 40: 1690-1691.

1072 Journal Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.Compatibility of levofloxacin with 34 medications during simulated Y-site administration.Am J Health-Syst Pharm 1999 ; 56: 1458-1459.

1091 Journal Petty C, Cunningham NL.Insulin adsorption by glass infusion bottles, polyvinylchloride infusion containers, and intravenous tubing.Anesthesiology 1974 ; 40: 400-404.

1175 Journal Hirsch JI, Wood JH, Thomas RB.Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. Am J Hosp Pharm 1981 ; 38: 995-997.

1193 Journal Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ.Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives.Am J Hosp Pharm 1983 ; 40: 1010-1012.

1201 Journal Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.Am J Hosp Pharm 1981 ; 38: 1919-1922.

1242 Journal Tol A, Quik RFP, Thyssen JHH.Adsorption of human and porcin insulins to intravenous administration sets.Pharm Weekbl [Sci] 1988 ; 10: 213-216.

1245 Journal Doglietto GB, Bellantone R, Bossola M, Perri V, Ratto C, Pacelli F, Sofo L, Migliore A, Manna R, Crucitti F.Insulin adsorption to three-liter ethylen vinyl acetate bags during 24-hour infusion.JPEN 1989 ; 13: 539-543.

1415 Journal Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.Compatibility of medications with 3-in-1 parenteral nutrition admixtures.JPEN 1999 ; 23: 67-74.


1506 Journal Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D.Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.EJHP 2015 ;22:107-112.

1802 Journal Bell MS, Nolt DH.Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive carenursery.Am J Health-Syst Pharm 2003 ; 60: 193-194.

1902 Journal Walker SE, Wyllie A, Law S.Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.Can J Hosp Pharm 2004 ; 57, 2: 90-96.

2017 Journal Barker B, Feddema S, Rusho WJ, Dengg R.Visual compatibility of vasopressin with other injectable drugs.Am J Health-Syst Pharm 2005 ; 62: 1969-1976.

2090 Journal Pere H, Chasse V, Forest JM, Hildgen P.Compatibility of injectable pantoprazole in Y-site administration.Pharmactuel 2004 ; 37: 193-196.

2091 Journal Lim SC, Roberts MJ, Paech MJ, Peng L, Jones A.Stability of insulin aspart in normal saline infusion.J Pharm Pract and Res 2004 ; 34: 11-13.

2108 Journal Trusley C, Kupiec TC, Trissel LA.Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.Int J Pharm Compound 2006 ; 10: 230-232.

2109 Journal Pelletier E, Forest JM, Hildgen P.Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.Pharmactuel 2006 ; 39: 71-75.

2141 Journal Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration bycontinuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and toadministration in intensive care units.J Antimicrob Chemother 2003 ; 51: 651-658.

2164 Journal Voges M, Divinop-Filho JC, Faict D, Somers F, Vermeulen P.Compatibility of insulin over 24 hours in standard and bicarbonate-based peritoneal dialysis solutions contained inbags made of different materials.Perit Dial Int 2006 ; 26, 4: 498-502.

2231 Journal de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients withnosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.J Antimicrob Chemother 2008 ; 61, 2: 382-388.

2233 Journal Condie C.K, Tyler L.S, Barker B, Canann D.M.Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site deliveryAm J Health-Syst Pharm 2008 ; 65, 5: 454-457.

2247 Journal Chan P, Heatherly K, Kupiec T.C, Trissel L.A.Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.Int J Pharm Compound 2008 ; 12, 3: 276-278.

2262 Journal Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.Compatibility of doripenem with other drugs during simulated Y-site administratioNAm J Health-Syst Pharm 2008 ; 65: 1261-1265.

2269 Journal Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.

3012 Journal Sullivan T, Forrest J.M, Leclair G.Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.


3134 Journal Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM.Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.Enferm Intensiva 2010 ; 21: 96-103.

3152 Journal Kumar A, Mann HJ.Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-siteadministration.Am J Health-Syst Pharm 2010 ; 67: 1640-1644.

3176 Poster Humbert Delaloye V, Berger M, Voirol P, Pannatier A.Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté.16èmes JFSPH, Sion, 18-19 novembre 2010

3210 Journal Jasti Bhaskara R, Saraf Poonam.Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.Int J Pharm Compound 2011 ; 15, 3: 259-261.

3212 Journal Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos.Enferm Intensiva 2011 ;22:78-82.

3216 Journal Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.Pharmactuel 2011 ; 44, 1 : 14-18

3224 Journal Fleury-Souverain S, Sigrist T, Griffiths W, Ing H, Matthey B; Sadeghipour F, Bonnabry P.The stability of soluble insulin in plastic syringesEJHP Science 2011 ; 1: 3-6.

3249 Journal Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 2011 ; 68: 2163-2169.

3310 Journal Greenwood B.C, Chesnick M.A, Szumita P.M, Caryn Belisle C, Cotugno M.Stability of Regular Human Insulin Extemporaneously Prepared in 0.9% Sodium Chloride in a Polyvinyl ChlorideBag.Hosp Pharm 2012 ; 47, 5: 367-370.

3372 Journal Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.Rev Bras Anestesiol 2013 ; 63, 1: 163-166.

3385 Journal Raverdi V, Ampe E, Hecq JD, Tulkens PM.Stability and compatibility of vancomycin for administration by continuous infusion.J Antimicrob Chemother 2013 ; 68: 1179-1182.

3408 Journal Tollec S, Touzin K, Pelletier E, Forest J.M.Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.Pharmactuel 2013 ; 46, 1 : 16-21.

3429 Journal Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S.Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486

3464 Journal Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, BàrbaraRibas-Nicolau.Compatibilidad física de la amiodarona en perfusión continuaEnferm Clin 2011 21:25-29.

3465 Journal E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?.Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua.Enferm Intensiva 2010 ;21:96-103.

3466 Journal B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau.Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivosEnferm Intensiva 2011 ;22:78-82.

3564 Manufacturer Rocuronium B Braun - Résumé des caractéristiques du produit.B Braun 2012


3580 Manufacturer Cytarabine Accord - Résumé des caractéristiques du produitAccord Healthcare France 2016

3766 Journal Forrest J.M, Hildgen P.Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuelsPharmactuel 2014 ; 47, 3 : 161-165.

3767 Journal Legris M.E, Lavoie A, Forrest J.M, Hildgen P.Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicamentsusuels.Pharmactuel 2014 ; 47, 3 : 167-172.

3781 Journal Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier AScreening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasicpotassium phosphate and furosemide.EJHP 2015 ;22:1 56-58

3823 Journal Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.Compatibilité physique de médicaments administrés dans l’unité de soins intensifs

Pharmactuel 2015 ; 48, 3 : 146-152.3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.

Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.ASHP Midyear 2015 2015

3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.ASHP Midyear 2015 2015

3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.Compatibility of isavunazonium sulfate during simulated Y-site administration.ASHP Midyear 2015 2015

3964 Journal Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.Pharmactuel 2017 ; 50,1 : 27-33.

4055 Journal Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.Am J Health-Syst Pharm 2018 , 75, 1:36-44

4119 Poster Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P.Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®)Hôpitaux Universitaire de Genève 2004

4145 Journal Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.Am J Health-Syst Pharm 2018 ;75,14:1048-1056

4254 Journal D'Huart E, Vigneron J, Demoré B.Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study andPhysical Compatibility Laboratory Tests on Anti-Infective DrugsPharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40

4309 Journal Lull M.E, Piacentino J.J, Traina A.N.Stability of U-500 regularinsulin in prefilled syringesJ Am Pharm Assoc 2013 ; 53, 3: 304-306.

4319 Journal Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.Hosp Pharm 2020 ; 55, 5: 332-337.

4332 Poster Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI)Compatibilité de Glycophos® avec d’autres médicaments administrés en perfusion aux soins intensifs (SI).JFSPH 2019 2019


4389 Journal Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, lelévosimendan et la kétamine.Pharmactuel 2019 ;52,4:206-213

4419 Journal Holt R.J, Siegert S.W.K, Krishna A.Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.

4433 Journal Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous MedicationsClin Ther 2020 ; 42, 3: 475-485.

4434 Journal Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-siteAdministration.Clin Ther 2019 ; 41, 10: 2162-2170.

4491 Journal De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A.Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.Eur J Pedia 2020

4528 Journal Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.Int J Pharm Compound 2021 ;25,1:52-61

4543 Journal Senarathna G, Strunk T, Petrovski M, Batty K.Physical compatibility of pentoxifylline and intravenous medications.Archives of Disease in Childhood 2018 ;104:292–295.

4567 Journal Henry H, Lannoy D, Maboudou P, Seguy D, Dine T, Pigny P, Odou P.Addition of Regular Insulin to Ternary Parenteral Nutrition: A Stability Study.Pharmaceutics 2021 ;13, 458.

4603 Journal Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-siteAdministration.Hosp Pharm 2021 ; 56, 4: 228-234.


Dictionary

Glucose-lowering InjectionTradename Stability in solutionsContainer MoleculeConcentration TemperatureStorage Length of timeBiosimilar Conflicting dataReferences Polyvinyl chlorideSodium chloride 0,9% Protect from lightDay Hour Dianéal® PD4 1.36% glucose (Baxter) Not specifiedPhysionéal® 1.36 (Baxter) PolyethyleneNone Polypropylene and polyethylenePolypropylen Syringe Stability of mixturesSolvent CompoundGlass LightFactors which affect stability FiltrationInduces AdsorptionEthylene vinyl acetate CompatibilityImmediate turbidity IncompatibleGlucose 5% CompatibleNaCl 0,9% or Glucose 5% Water for InjectionRinger’s lactate solution Turbidity in one hourUnspecified incompatibility Immediate precipitationColor change after 24 hours Precipitation after 4 hoursPrecipitation after 1 hour Parenteral nutrition (binary mixture)Chemical instability Parenteral nutrition (with lipids)Route of administration IntravenousContinuous infusion IntramuscularSub-cutaneous IntraperitonealContinuous subcutaneous infusion References


Dictionary


Documents

Stabilis - Monographie - Insulin